Skip to main content

Table 3 OS multivariate analysis on FAS and FAS CORRECT populations

From: Survival, safety, and prognostic factors for outcome with Regorafenib in patients with metastatic colorectal cancer refractory to standard therapies: results from a multicenter study (REBECCA) nested within a compassionate use program

Overall survival Hazard ratio (95 % CI) P Relative weight
FAS Population
 ECOG Performance Status   <0.001  
  0 1   0
  1 1.54 (1.26–1.88)   +2
  ≥ 2 3.43 (2.50–4.70)   +4
 Time since initial diagnosis   <0.001  
  ≥ 18 months 1   0
  < 18 months 1.72 (1.40–2.13)   +2
 Initial daily dose of regorafenib   0.042  
  160 1   0
  < 160 1.26 (1.01–1.57)   +1
 Number of metastatic sites   0.020  
  < 3 1   0
  3+ 1.29 (1.04–1.60)   +1
 Liver metastases   <0.001  
  No 1   0
  Yes 1.61 (1.29–2.01)   +2
 KRAS   0.016  
  Wild-type 1   0
  Mutated 1.25 (1.04–1.49)   +1
FAS CORRECT Population
 ECOG Performance Status   0.001  
  0 1   0
  1 1.45 (1.16–1.81)   +1
  ≥ 2    
 Time since initial diagnosis   0.001  
  ≥ 18 months 1   0
  < 18 months 1.55 (1.21–1.99)   +1
 Number of metastatic sites   0.013  
  < 3 1   0
  3+ 1.38 (1.07–1.77)   +1
 Liver metastases   <0.001  
  No 1   0
  Yes 1.65 (1.28–2.13)   +1